Imunon, Inc.: IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 doseResults ...
The American Journal of Managed Care4d
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...
Hosted on MSN5d
Harmine has no major psychoactive effects
A study examining the effects of harmine, a major component of ayahuasca, found that it produces no significant psychoactive ...
urologytimes5d
Casdatifan is linked with promising safety, efficacy in clear cell RCC
The 100 mg/day dosage of casdatifan is planned for future combination ... 1 Data from the phase 1 ARC-20 trial (NCT05536141), a dose-escalation and dose-expansion study of casdatifan, were presented ...
The Brighterside of News on MSN6d
Identical twin study reveals whether vegan or meat-based diets are healthier
The saying "You are what you eat" has never been more relevant, especially when it comes to cardiovascular health. While plant-based diets have long been associated with heart benefits, new research ...
Business Wire6d
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...